HemaCare Corp., saddled with research and development costs for an experimental AIDS treatment, reported a third-quarter loss of $146,000.
A year earlier, HemaCare earned $53,000. Its revenue in the latest quarter increased 32%, to $3.13 million from $2.36 million.
The Sherman Oaks supplier of blood-related products and services lost $782,000 in the latest nine-month period, in contrast with a $311,000 loss in the first nine months of 1991. Its revenue totaled $9.05 million, up 44% from $6.27 million.